Abeona Therapeutics Inc (NASDAQ:ABEO) CFO Joseph Walter Vazzano Acquires 5,608 Shares of Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) CFO Joseph Walter Vazzano purchased 5,608 shares of the business’s stock in a transaction dated Thursday, April 25th. The shares were purchased at an average cost of $3.14 per share, for a total transaction of $17,609.12. Following the completion of the purchase, the chief financial officer now directly owns 233,868 shares of the company’s stock, valued at approximately $734,345.52. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Abeona Therapeutics Trading Up 2.2 %

Shares of ABEO stock opened at $3.26 on Friday. The stock has a 50 day simple moving average of $7.31 and a two-hundred day simple moving average of $5.61. Abeona Therapeutics Inc has a fifty-two week low of $2.83 and a fifty-two week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, analysts forecast that Abeona Therapeutics Inc will post -2.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ABEO. StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC bought a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $199,000. Worth Venture Partners LLC boosted its position in shares of Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 121,969 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Abeona Therapeutics by 84.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock valued at $13,682,000 after buying an additional 1,488,834 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Abeona Therapeutics during the third quarter valued at approximately $648,000. Finally, AIGH Capital Management LLC boosted its position in shares of Abeona Therapeutics by 77.7% during the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock valued at $4,779,000 after buying an additional 496,278 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.